Company Profile

Pharmaengine Inc Taipei Exchangestock Code 4162 Twobegan Operations In 2003Is A Commercial Stage Pharmaceutical Company Dedicated To Developing Medicines For Cancer Patientswe Are Currently Focusing On Precision Oncology Related To Dna Damage Responseddrpathwayspep07An Orally Bioavailable Small Molecule Chk1 Inhibitor With Brain Penetrating Propertiesis Currently In Phase 1 Clinical Studies For Acute Myeloid Leukemiaaml Mantle Cell Lymphomamcl Or Advanced Metastatic Solid Tumorsour Preclinical Pipeline Includes Other Targets In The Ddr Pathways Aiming To Provide Synergy When In Combinations With Chemo Radiation Therapies Or With Other Precision Oncology Medicinesin The Pastpharmaengine Successfully Developed And Out Licensed Its First Commercial Productonivydeliposomal Irinotecan For The Treatment Of Metastatic Pancreatic Adenocarcinomait Is Also Responsible For The Commercialization Of Onivyde In Taiwanwe Strongly Believe In Building A Sustainable Business And Work Environment With Our Six Core Valueswe Encourage Employees To Havesense Of Urgencyand Adoptcritical Thinkingwhen Facing Dynamic Environments And Challenges That Require Rapid Responseswe Wish To Build A Work Environment Withdiversityand A Space Forcontinuous Learning And Growthas We Believe Inclusivity And Room For Growth Are Crucial To Employee Welfare Teamworkis Crucial In New Drug Development And We Hope Through Considerate Communication And Sharingeach Member Can Utilize Their Specialties And Feel Valuedlastlywe Put Great Emphasis On Helping Each Member Achieve Their Individualwork And Life Balancein Different Stages Of Lifefor More Informationplease Visit Our Company Website